< Back to previous page

Project

RSV impact and cost effectiveness modelling in low- and middle-income countries.

There are few preventive RSV interventions available and these are generally too expensive for widespread use outside of high-income regions. There are additional RSV preventive interventions under development including maternal RSV vaccines to protect infants as well as monoclonal antibody approaches to be given to infants. PATH has developed an RSV impact and cost effectiveness model for RSV interventions. The purpose of this work is to develop another model for comparison purposes.
Date:1 Nov 2017 →  30 Sep 2023
Keywords:IMMUNISATION PROGRAMMES, HEALTH ECONOMICS
Disciplines:Public health care, Public health sciences, Public health services